X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SUVEN LIFE VENUS REMEDIES/
SUVEN LIFE
 
P/E (TTM) x -8.5 17.3 - View Chart
P/BV x 0.1 3.6 3.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   SUVEN LIFE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
SUVEN LIFE
Mar-18
VENUS REMEDIES/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs143251 56.9%   
Low Rs65155 41.9%   
Sales per share (Unadj.) Rs324.249.1 659.9%  
Earnings per share (Unadj.) Rs6.49.7 66.0%  
Cash flow per share (Unadj.) Rs40.611.4 356.2%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs366.060.3 607.0%  
Shares outstanding (eoy) m12.34127.28 9.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.1 7.8%   
Avg P/E ratio x16.220.9 77.6%  
P/CF ratio (eoy) x2.617.8 14.4%  
Price / Book Value ratio x0.33.4 8.4%  
Dividend payout %015.4 0.0%   
Avg Mkt Cap Rs m1,28225,825 5.0%   
No. of employees `0000.91.1 84.2%   
Total wages/salary Rs m251613 41.0%   
Avg. sales/employee Rs Th4,430.15,832.6 76.0%   
Avg. wages/employee Rs Th278.0571.5 48.6%   
Avg. net profit/employee Rs Th87.61,153.8 7.6%   
INCOME DATA
Net Sales Rs m4,0006,253 64.0%  
Other income Rs m23233 9.8%   
Total revenues Rs m4,0236,485 62.0%   
Gross profit Rs m7851,982 39.6%  
Depreciation Rs m422213 197.8%   
Interest Rs m34446 742.3%   
Profit before tax Rs m421,955 2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37718 -5.2%   
Profit after tax Rs m791,237 6.4%  
Gross profit margin %19.631.7 61.9%  
Effective tax rate %-87.936.7 -239.2%   
Net profit margin %2.019.8 10.0%  
BALANCE SHEET DATA
Current assets Rs m2,6065,622 46.4%   
Current liabilities Rs m1,9801,168 169.6%   
Net working cap to sales %15.671.2 22.0%  
Current ratio x1.34.8 27.3%  
Inventory Days Days12881 157.6%  
Debtors Days Days4336 120.1%  
Net fixed assets Rs m5,3533,325 161.0%   
Share capital Rs m123127 96.9%   
"Free" reserves Rs m4,3937,547 58.2%   
Net worth Rs m4,5167,674 58.8%   
Long term debt Rs m1,61814 11,641.7%   
Total assets Rs m8,2919,135 90.8%  
Interest coverage x1.143.2 2.6%   
Debt to equity ratio x0.40 19,782.9%  
Sales to assets ratio x0.50.7 70.5%   
Return on assets %5.114.0 36.3%  
Return on equity %1.816.1 10.9%  
Return on capital %6.326.0 24.2%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m05,066 0.0%   
Fx outflow Rs m7362,001 36.8%   
Net fx Rs m-7363,065 -24.0%   
CASH FLOW
From Operations Rs m997699 142.6%  
From Investments Rs m-461-6 7,562.3%  
From Financial Activity Rs m-571-577 99.0%  
Net Cashflow Rs m-35116 -30.2%  

Share Holding

Indian Promoters % 32.9 63.4 51.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.5 181.9%  
Shareholders   20,121 37,287 54.0%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal & Realty Stocks Drag(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.1% while the Hang Seng is down 0.5%.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 16, 2018 11:53 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS